Skip to main content
METABIOMED.CO.,LTD logo

METABIOMED.CO.,LTD — Investor Relations & Filings

Ticker · 059210 ISIN · KR7059210005 KO Manufacturing
Open in API
Filings indexed 216 across all filing types
Latest filing 2026-04-06 Regulatory Filings
Country KR South Korea
Listing KO 059210

About METABIOMED.CO.,LTD

https://www.meta-biomed.com/

METABIOMED.CO.,LTD. is a developer and manufacturer of medical devices and biomaterials. The company's operations are organized into four primary business areas: Dental, Suture Material & Biomaterial, Meta Surgical, and Cosmetic Medical. Its dental division provides a range of equipment and materials, with its root canal filling product holding the largest global market share. The company also manufactures various synthetic absorbable surgical sutures, including Poliglecaprone (PGCL) and Polydioxanone (PDO) types. The surgical division offers devices for use in general surgery, orthopedics, neurosurgery, and obstetrics & gynecology. In the cosmetic medical field, it produces products such as PDO threads. METABIOMED distributes its products to over 100 countries through a global sales network.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Regulatory Filings Classification · 75% confidence The document is a Korean notice of the board resolution (‘주주총회소집결의’) to convene an extraordinary shareholders’ meeting (date, time, venue, record date). It is not presenting meeting materials (AGM-R), not a proxy statement with proposal details (PSI), not a dividend, capital change, or vote result, and contains no financial report. It is a general regulatory announcement of the meeting convocation, fitting the fallback category Regulatory Filings (RNS).
2026-04-06 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a corporate regulatory disclosure filed to the Financial Supervisory Service/Korea Exchange regarding the appointment, dismissal, or mid-term resignation of an outside director (사외이사). It details changes in the board of directors rather than financial results, dividends, or share transactions. This matches the definition of Board/Management Information.
2026-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is a summary of resolutions and voting results from the company’s regular shareholders’ meeting held on 2026-03-31. It lists items voted on, approval status, vote counts, and percentages. This clearly matches a Declaration of Voting Results for an AGM, so it falls under the DVA category.
2026-03-31 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 75% confidence The document is a voluntary self‐disclosure “기업가치 제고 계획” (corporate value enhancement plan) focused on dividend policy, high‐dividend classification, capital reserve reduction and investor communications. It is not a full annual or interim report, audit report, call transcript, M&A announcement, or formal dividend notice (it does not declare an actual dividend amount or record date). It also is not a proxy solicitation or governance code. While it touches on capital reserve reduction (a capital action), it is primarily a broad plan rather than a pure financing or capital structure update. There is no more specific category for a corporate value enhancement plan, so it falls into the general regulatory/disclosure bucket. Therefore, it is best classified under Regulatory Filings (RNS).
2026-03-31 Korean
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement of the company’s cash dividend decision, specifying per-share dividend amount (corrected from 100 to 105 KRW), record date (2025-12-31), payment date (2026-04-13), total dividend amount, approval bodies, and related details. This matches “Notice of Dividend Amount” filings, not a report publication or share issue. Hence, it is classified as DIV.
2026-03-24 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 98% confidence The document is the independent auditor’s report (감사보고서) for MetaBioMed Co., Ltd. including auditor’s opinion, financial statements, notes, and internal control audit opinion covering fiscal years ending December 31, 2025 and 2024. It is a standalone audit report and financial statements, not an announcement or summary. Therefore, it fits the Audit Report / Information category (AR). FY 2025
2026-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.